Stockscreener 앱 받기
0.5499
3.53%
-0.0201
전일 마감가:
$0.57
열려 있는:
$0.58
하루 거래량:
280.75K
Relative Volume:
0.99
시가총액:
$63.53M
수익:
-
순이익/손실:
$-168.86M
주가수익비율:
-0.3072
EPS:
-1.79
순현금흐름:
$-125.29M
1주 성능:
-3.36%
1개월 성능:
-29.28%
6개월 성능:
-29.38%
1년 성능:
-63.82%
1일 변동 폭
$0.5331
$0.5996
1주일 범위
$0.5153
$0.636
52주 변동 폭
$0.5153
$2.485
알로비르 Stock (ALVR) Company Profile
명칭
Allovir Inc
전화
(617) 433-2605
주소
1100 WINTER STREET, WALTHAM
ALVR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ALVR | 0.5499 | 63.53M | 0 | -168.86M | -125.29M | -1.79 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
알로비르 Stock (ALVR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2020-08-24 | 개시 | JP Morgan | Overweight |
| 2020-08-24 | 개시 | Morgan Stanley | Overweight |
| 2020-08-24 | 개시 | SVB Leerink | Outperform |
알로비르 주식(ALVR)의 최신 뉴스
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of INSI, LBRDA, ROIC and ALVR - The Malaysian Reserve
AlloVir falls after all-stock merger deal with Kalaris - MSN
AlloVir to combine with Kalaris Therapeutics in all-stock transaction - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investo - GuruFocus.com
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of IPXX, YOTA, IVCP and ALVR - GlobeNewswire Inc.
AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Drop in Short Interest - MarketBeat
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BSA bureau
Allovir stock plunges to 52-week low of $0.58 amid market challenges - Investing.com India
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - cnhinews.com
$hareholder Alert: The M&A Class Action Firm Launches Legal Inquiry the Merger ROIC, VINE, ALVR and CDMO - AccessWire
AlloVir and Kalaris enter merger to advance retinal disease therapies - Pharmaceutical Technology
AlloVir and Kalaris Therapeutics Announce Merger - FinSMEs
$hareholder Alert: The M&A Class Action Launches Legal Inquiry for the Merger of ROIC, VINE, ALVR and CDMO - AccessWire
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders - GlobeNewswire
ROIC, VINE, ALVR and CDMO Alert: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire
Items Tagged with 'TH-103' - BioWorld Online
With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger - BioCentury
Items Tagged with 'Kalaris Therapeutics Inc.' - BioWorld Online
Allovir sees a new direction with Kalaris merger - BioWorld Online
SEC Form 425 filed by AlloVir Inc. - Quantisnow
Kalaris to go public via reverse merger with AlloVir - BioPharma Dive
AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter
Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire
AlloVir and Kalaris Merge to Advance Retinal Therapies - TipRanks
AlloVir and Kalaris Therapeutics To Merge - citybiz
AlloVir Shares Slide Premarket on Reverse Merger With Kalaris Therapeutics - MarketWatch
AlloVir stock falls after Kalaris merger deal (ALVR:NASDAQ) - Seeking Alpha
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina - The Manila Times
AlloVir and Kalaris Therapeutics Announce Agreement for - GlobeNewswire
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.05% - MSN
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact The Gross Law Firm - GuruFocus.com
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks - Simply Wall St
Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Joi - GuruFocus.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely - Simply Wall St
AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat
ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to - GuruFocus.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Invest - GuruFocus.com
Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail
SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James - GuruFocus.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) - GuruFocus.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Allovir CEO Diana Brainard sells $7,596 in stock - Investing.com
Allovir's general counsel Edward Miller sells $1,082 in stock By Investing.com - Investing.com South Africa
Allovir's general counsel Edward Miller sells $1,082 in stock - Investing.com
Allovir's chief accounting officer Brett Hagen sells $746 in stock - Investing.com
알로비르 (ALVR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):